Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp.

Nova Mentis Expands Psychedelic Drug Pipeline

VANCOUVER,ย BC, Dec. 29, 2020 -ย Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF)ย ("NOVA") is pleased to announce that it has added two additional psychedelic compounds to its drug portfolio. NOVA has contracted with its U.S. partner to begin manufacturing the active pharmaceutical ingredients (API), baeocystin and aeru... Read More...

Think Research Corporation Announces Grant of Equity Compensation and Appointment of Chief Operating Officer

TORONTO, Dec. 22, 2020 - Eastwood Capital Corp. (the "Acquiror") has today filed an early warning report (the "Early Warning Report") advising of its acquisition of an aggregate of 2,211,400 common shares (the "Shares") of Automotive Finco Corp. (the "Company") through a private transaction. The Shares were purchased at a price of $1.50 p... Read More...

Early Warning Report for Eastwood Capital Corp.

VANCOUVER, BC, Nov. 2, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that, further to its news release dated October 9, 2020, it has entered into a definitive amalgamation agreement, (the "Definitive Agreement") with Pilz Bioscience Corp. ("Pilz") and 1271642 B.C. Ltd. ("Nova ... Read More...

Canada and Ontario invest in green infrastructure to support residents of Pays Plat First Nation and Biigtigong Nishnaabeg First Nation

VANCOUVER, BC, Dec. 3, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that it has appointed Dr. Marvin S. Hausman, MD as Chairman of its Scientific Advisory Board, effective immediately. Dr. Hausman is the Chief Medical Officer of Pilz Bioscience Corp., a wholly-owned subsidiar... Read More...

Canadians may overestimate their ability to spot phishing scams

VANCOUVER, BC, Nov. 5, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that its pending acquisition target, Pilz Bioscience Corp. ("Pilz"), has entered into a psilocybin manufacturing agreement with a U.S. based pharmaceutical company with over 800 employees. Pilz will have comp... Read More...

Nova Mentis Life Science Acquisition Target, Pilz Bioscience Corp, Provides Corporate Update

VANCOUVER, BC, Nov. 11, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that its pending acquisition target, Pilz Bioscience Corp. ("Pilz"), has provided a corporate update.Dr. Marvin S. Hausman MD, Chairman and Chief Scientific Officer of Pilz commented: "We are very pleased wi... Read More...

Nova Mentis Life Science Acquisition Target, Pilz Bioscience Corp, Signs Psilocybin Manufacturing Agreement

VANCOUVER, BC, Nov. 5, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF)ย ("NOVA")ย is pleased to announce that its pending acquisition target, Pilz Bioscience Corp. ("Pilz"), has entered into a psilocybin manufacturing agreement with a U.S. based pharmaceutical company with over 800 employees. Pilz will have comp... Read More...

Nova Mentis Life Science Signs Amalgamation Agreement to Acquire 100% of Pilz BioScience Corp.

VANCOUVER, BC, Nov. 2, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that, further to its news release dated October 9, 2020, it has entered into a definitive amalgamation agreement, (the "Definitive Agreement") with Pilz Bioscience Corp. ("Pilz") and 1271642 B.C. Ltd. ("Nova ... Read More...